Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2004 1
2010 1
2015 3
2016 2
2018 1
2020 2
2021 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.
Choi EM, Lacarra B, Afolabi MO, Ale BM, Baiden F, Bétard C, Foster J, Hamzé B, Schwimmer C, Manno D, D'Ortenzio E, Ishola D, Keita CM, Keshinro B, Njie Y, van Dijck W, Gaddah A, Anumendem D, Lowe B, Vatrinet R, Lawal BJ, Otieno GT, Samai M, Deen GF, Swaray IB, Kamara AB, Kamara MM, Diagne MA, Kowuor D, McLean C, Leigh B, Beavogui AH, Leyssen M, Luhn K, Robinson C, Douoguih M, Greenwood B, Thiébaut R, Watson-Jones D; EBOVAC-3/EBL2005 Study Team. Choi EM, et al. Lancet Glob Health. 2023 Nov;11(11):e1743-e1752. doi: 10.1016/S2214-109X(23)00410-2. Lancet Glob Health. 2023. PMID: 37858585 Free article. Clinical Trial.
Clinical Characteristics and Aetiology of Uveitis in a Viral Haemorrhagic Fever Zone.
Balendra S, Williams L, Mustapha J, Koroma Z, Kamara A, Conteh O, Kanu T, Saradugu B, Kamara S, Ward L, Wang H, Fashina T, Koroma S, Shantha J, Yeh S, Kennedy A. Balendra S, et al. Among authors: koroma s. Res Sq [Preprint]. 2023 Aug 8:rs.3.rs-3222203. doi: 10.21203/rs.3.rs-3222203/v1. Res Sq. 2023. PMID: 37609303 Free PMC article. Preprint.
Ribavirin for Lassa fever postexposure prophylaxis.
Hadi CM, Goba A, Khan SH, Bangura J, Sankoh M, Koroma S, Juana B, Bah A, Coulibaly M, Bausch DG. Hadi CM, et al. Among authors: koroma s. Emerg Infect Dis. 2010 Dec;16(12):2009-11. doi: 10.3201/eid1612.100994. Emerg Infect Dis. 2010. PMID: 21122249 Free PMC article. No abstract available.
Prognostic Analysis of Patients with Ebola Virus Disease.
Zhang X, Rong Y, Sun L, Liu L, Su H, Zhang J, Teng G, Du N, Chen H, Fang Y, Zhan W, Kanu AB, Koroma SM, Jin B, Xu Z, Song H. Zhang X, et al. Among authors: koroma sm. PLoS Negl Trop Dis. 2015 Sep 23;9(9):e0004113. doi: 10.1371/journal.pntd.0004113. eCollection 2015 Sep. PLoS Negl Trop Dis. 2015. PMID: 26398207 Free PMC article.
Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients.
Li J, Duan HJ, Chen HY, Ji YJ, Zhang X, Rong YH, Xu Z, Sun LJ, Zhang JY, Liu LM, Jin B, Zhang J, Du N, Su HB, Teng GJ, Yuan Y, Qin EQ, Jia HJ, Wang S, Guo TS, Wang Y, Mu JS, Yan T, Li ZW, Dong Z, Nie WM, Jiang TJ, Li C, Gao XD, Ji D, Zhuang YJ, Li L, Wang LF, Li WG, Duan XZ, Lu YY, Sun ZQ, Kanu ABJ, Koroma SM, Zhao M, Ji JS, Wang FS. Li J, et al. Among authors: koroma sm. Int J Infect Dis. 2016 Jan;42:34-39. doi: 10.1016/j.ijid.2015.10.021. Epub 2015 Oct 30. Int J Infect Dis. 2016. PMID: 26523640 Free PMC article.
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Köhn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Greenwood B, Leyssen M, Douoguih M, Leigh B, Watson-Jones D; EBL3001 study group. Afolabi MO, et al. Lancet Infect Dis. 2022 Jan;22(1):110-122. doi: 10.1016/S1473-3099(21)00128-6. Epub 2021 Sep 13. Lancet Infect Dis. 2022. PMID: 34529962 Free PMC article. Clinical Trial.
Serological Investigation of Laboratory-Confirmed and Suspected Ebola Virus Disease Patients During the Late Phase of the Ebola Outbreak in Sierra Leone.
Liu Y, Sun Y, Wu W, Li A, Yang X, Zhang S, Li C, Su Q, Cai S, Sun D, Hu H, Zhang Z, Yang X, Kamara I, Koroma S, Bangura G, Tia A, Kamara A, Lebby M, Kargbo B, Li J, Wang S, Dong X, Shu Y, Xu W, Gao GF, Wu G, Li D, Liu WJ, Liang M. Liu Y, et al. Among authors: koroma s. Virol Sin. 2018 Aug;33(4):323-334. doi: 10.1007/s12250-018-0044-z. Epub 2018 Jul 31. Virol Sin. 2018. PMID: 30066045 Free PMC article.
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
Ishola D, Manno D, Afolabi MO, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Köhn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Leyssen M, Greenwood B, Douoguih M, Leigh B, Watson-Jones D; EBL3001 study group. Ishola D, et al. Lancet Infect Dis. 2022 Jan;22(1):97-109. doi: 10.1016/S1473-3099(21)00125-0. Epub 2021 Sep 13. Lancet Infect Dis. 2022. PMID: 34529963 Free PMC article. Clinical Trial.
15 results